For patients with advanced cervical cancer, cisplatin plus pemetrexed may be effective
the ONA take:
According to a new study published in the Journal of Clinical Oncology, cisplatin plus pemetrexed improved response rates and survival rates of patients with advanced cervical cancer. In the phase 2 study, researchers assigned patients with advanced, persistent, or recurrent cervical cancer to received either cisplatin in combination with pemetrexed or paclitaxel.
Researchers found that patients with no prior history of chemotherapy that received cisplatin plus pemetrexed had a 31% response rate for a duration of up to 7 months and an overall survival of 12 months. Patients that received cisplatin plus paclitaxel had a 29% response rate for a duration of up to 6 months and an overall survival of 13 months.
Furthermore, the pemetrexed combination was observed to be less toxic compared with the paclitaxel combination. Researchers also observed increased survival rates when adding bevacizumab to the paclitaxel combination, so researchers suggest possibly adding bevacizumab to the pemetrexed combination.
According to the Centers for Disease Control and Prevention (CDC), cervical cancer used to be the leading cause of cancer-related death in women in the United States, but regular Pap screenings have led to early cancer detection and decreased mortality.
Cisplatin plus pemetrexed improved response rates in patients with advanced cervical cancer.
Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds.
The cancer-fighting cocktail, which combines the chemotherapy drug cisplatin with pemetrexed - an agent that stops cancer cells from dividing - showed promising results for advanced, persistent, or recurrent cervical cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|